entertainment -WSS

entertainment

author：leisure time 2025-10-02 19:38:07 - browse：9798

Intellia Therapeutics said Sunday that the first 10 patients to receive a CRISPR-based treatment for hereditary angioedema, a genetic disease, saw their swelling attacks — the condition’s hallmark symptom — virtually eliminated for an average of 20 months and counting.

The attacks were reduced by an average of 98%. One patient has remained attack-free for 26 months. Two patients who suffered particularly frequent attacks, experiencing 14 and 16.8 per month, respectively, have now gone more than 20 months since their last attack.

No patient has had an attack in the last 11 months of follow-up, according to the data presented at the European Academy of Allergy and Clinical Immunology Congress. All side effects were either grade 1 or 2 on a 5-grade scale.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： How Robert F. Kennedy Jr. distorted vaccine science

focus

WSS

The biotech scorecard for Q3: 15 stock

FDA's Woodcock to retire early next year

Gain of function research would be limited under House proposal

Surge of respiratory disease in China has likely explanation

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

Crowdfunding for unproven stem cell procedures spreads misinformation

hotspot

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

After affirmative action ruling, medical educators look to 'holistic review'

The biotech scorecard for Q3: 15 stock

BioMarin wins approval for gene therapy to treat hemophilia A

Use doctors trained outside the U.S. to ease the physician shortage

Novavax promises a turnaround & Lilly roils the obesity market

A letter from the executive editor: The 2023 STATUS List

Wildfire smoke exposes gaps in outdoor worker protections

The biotech scorecard for Q3: 15 stock

New air purifier tech could be key to improving indoor air quality

Readout LOUD podcast: A CRISPR milestone, biotech mixology

focus

A letter from the executive editor: The 2023 STATUS List

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

Gain of function research would be limited under House proposal

PBM reforms clear House panel

Vertex cell therapy lets patients with type 1 diabetes stop insulin

A letter from the executive editor: The 2023 STATUS List

focus

Wikipedia

focus

Wikipedia